

PC10754AJTJ

an envelope

CCENTAGE

ACCENTAGE

ACCENTAG

| Thereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this | | | | | | | | | | | | | |
|--|--|--|--|--|--|--|--|--|--|--|--|--|--|
| By | | | | | | | | | | | | | |
| (Signature of person mailing) | | | | | | | | | | | | | |
| - Fotricia Citch field | | | | | | | | | | | | | |
| (Typed or printed name of person) | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| IN THE UNITED STATES PATENT AND TRADEMARK OFFICE | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| APPLICANTS: | | | | | | | | | | | | | |
| William J. Curatolo, et al. : Group Art Unit: 1615 | | | | | | | | | | | | | |
| Examiner: B. M. Fubara | | | | | | | | | | | | | |
| PATENT NO.: 09/918,127 : | | | | | | | | | | | | | |
| FOR: Pharmaceutical Compositions of Cholesteryl Ester Transfer Protein Inhibitor: | | | | | | | | | | | | | |
| FILED: July 30, 2001 | | | | | | | | | | | | | |
| Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450 | | | | | | | | | | | | | |
| Sir: | | | | | | | | | | | | | |

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

The Commissioner is hereby authorized to charge the sum of \$180.00 to Deposit Account No. 16-1445 to cover the cost of this submission in accordance with 37 CFR 1.97(c) and 1.17(p). The Commissioner is further authorized to charge any additional fees which may be required under 37 CFR 1.16 and 1.17, or credit any overpayment, to Account No. 16-1445.

A prompt and favorable response is earnestly solicited.

Respectfully submitted.

November 18, 2004

James T. Jones

Attorney for Applicant(s)

Reg. No. 30,561

Pfizer Inc. Patent Department, Box 8260-1611 Eastern Point Road Groton, CT 06340 (860) 441-4903

| INFORMATION DISCLOSURE CITATION | | | | | | | ATTY. DOCKET NO. PC10754AJTJ | | | | | SERIAL NO. 09/918,127 | | | | |
|-----------------------------------|-----------------------------|----------------------------|--|--|-------------------|----------|---------------------------------------|----------------|--|----------------|---------------|--|------------------|--------------------|--|--|
| (Use several sheets if necessary) | | | | | | | APPLICANT William J. Curatolo, et al. | | | | | | | | | |
| FILING DA | | | | | | | | ΓΕ July | y 30, 2001 GROUP 1615 | | | | | | | |
| U.S. PATENT DOCUMENTS | | | | | | | | | | | | | | | | |
| EXAMPLE DOCUMENT NUMBER | | | | | | | | | DATE | NAM | NAME | | SUBCLASS | FILING IF APERI | G DATE COFFCATE | |
| | US | 2004 | 0 | 0 | 1 | 3 | 7 | 34 | 22 Jan. 2004 | Babcocl | k et al | 424 | 488 | | _ | |
| | | | | | | | | | | | | | | | | |
| | | + | | | - | | + | | | | | | - | | | |
| | <u> </u> | | | | | | | | | | | | <u> </u> | - | | |
| | | - | | — | | | <u> </u> | <u> </u> | | | | ļ! | - | <u> </u> | | |
| | | | | | | | | <u> </u> | | | | | | | | |
| | FOREIGN PATENT DOCUMENTS | | | | | | | | | | | | | | | |
| ļ | | | DO | CUMENT NU | JMBER | | | | DATE | COUNTR | tY | CLASS | SUBCLASS | TRANS | TRANSLATION | |
| | | | | | | | | | | | | | | YES | NO | |
| | wo | 0 | 1 | 4 | 0 | 1 | 9 | 0 | 7 June 01 | Internatio | nal | C07D | 215/42 | | | |
| | | | | | | | | | | | | | | | | |
| | wo | 9 | 8 | 0 | 4 | 5 | 2 | 8 | 5 Feb 98 | Internatio | International | | 213/20 | | | |
| | wo | 0 | 0 | 7 | 2 | 8 | 2 | 5 | 7 Dec 00 | Internatio | International | | 9/14 | | | |
| | \sqcup | | <u> </u> | <u> </u> | \perp | | | <u> </u> | | | | | | | <u> </u> | |
| | | | | | | | | | | | | | | | | |
| | | | ОТН | ER DO | CUMENT | S (In | icluding A | Luthor, 1 | Title, Date, Per | rtinent Pa | ges, Et | tc.) | | | | |
| | | Mortin | -4-al C | | | | 1.05-minal | · Orientale | · # - Pharman | "! Cala | - 40 | | | | | |
| | + | Marun | Martin et al., Physical Pharmacy, Physical Chemical Principles in the Pharmaceutical Sciences, 1969, 2 ed., chapter 4, pg 85 | | | | | | | | | | | | | |
| | + | | | | | | | | | | | | | | | |
| <u> </u> | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| -VARMAIE | | | | | | | | | | · | | | | | | |
| EXAMINE | R | | | | | | | DATEC | CONSIDERED | | | | | | | |
| | | | | | | | | | | | | | | | | |
| EXAMINER: I next communi | Initial if re ication to | ference con: applicant. | sidered, whe | ather or not c | itation is in cor | aformanc | æ with MPEP 6 | i09; Draw line | e through citation if not | in conformance | and not co | onsidered. I | nclude copy of t | this form | with | |

. . .

Conforms with FORM PTO-FB-A820